“龙头药企,一指尽揽”,国内首只药ETF(562050)今日上市

格隆汇
Jun 19, 2025

在有关医药的热议依然“霸榜”不少投资社区及平台时,国内首只药ETF(562050)今日正式上市交易。据悉,药ETF(562050)是国内首只跟踪中证制药指数、投资着眼点清晰界定于制药领域的的ETF产品,投资者通过药ETF(562050)将有望“龙头药企,一指尽揽”,深入涉足门槛较高的医药领域并相应在其中把握投资机遇。 据悉,药ETF(562050)的标的指数中证制药指数在行业配置上覆盖化学药、生物药品、中药三大类纯制药子行业,同时并不涉及CXO、疫苗、血制品、医疗器械,这使得它与目前其他一些医药基金产品形成了鲜明的差异化竞争。 分析人士指出,“药”是人类永恒的需求,我国人口基数庞大、人口老龄化加速、人均GDP提升,正是驱动制药行业长期高景气度的坚实底层逻辑。同时,药ETF(562050)充分秉持了“精选龙头”的思路,标的指数“中证制药指数”汇聚了以上三大制药领域最具代表性的龙头上市公司,如恒瑞医药、百济神州等,都是今年以来备受市场追捧的焦点个股,也是化学药、生物药品领域的领军企业之一。根据中证指数公司数据,截至2025.5.31,该指数前十大成份股合计权重占比已达49.36%,重仓龙头的特征十分显著。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10